TP03HN106

TP03HN106 · Talengen Institute of Life Sciences

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TP03HN106, covering 2025-04-15 to 2025-04-15. Get the full timeline:

Most recent: Clinical Trial Update: TP03HN106 in Patients With Critical Limb Ischemia [Phase 2]